Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

22 de abril de 2015 atualizado por: AstraZeneca

Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 500 mg Metformin (Glucophage Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis) tablets coadministered to healthy participants in the fasted and fed states.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

27

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Texas
      • Austin, Texas, Estados Unidos, 78744
        • PPD Development, LP

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 55 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Men and women, aged 18 to 55 years, inclusive
  • Healthy participants as determined by a lack of clinically significant deviation from normal in medical history, physical examination, electrocardiograms, and clinical laboratory determinations
  • Body Mass Index of 18 to 32 kg/m^2, inclusive

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months) gastrointestinal disease
  • Any major surgery within 4 weeks of study drug administration
  • History of allergy to DPP-4 inhibitors or related compounds
  • History of allergy or intolerance to metformin or other similar acting agents
  • Previous exposure to saxagliptin
  • Exposure to metformin within 3 months pervious to study drug administration
  • Estimated creatinine clearance of <80 mL/min using the Cockcroft Gault formula

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)
Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Outros nomes:
  • Onglyza™
  • Glucophage™
Outro: Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)
Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
Outro: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Outros nomes:
  • Onglyza™
  • Glucophage™
Outro: Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)
Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Observed Maximum Plasma Concentration (Cmax) of Saxagliptin, Tablets and Fixed-dose Combination (FDC), Administered to Participants in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Observed Cmax of Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Terminal Half-life (t1/2) of Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-t]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
AUC[0-t] for Metformin, Tablets and FDC, Given in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
AUC From Time 0 Extrapolated to Infinity (AUC[0-inf]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
AUC[0-inf] for Metformin, Tablets and FDC, Administered in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States
Prazo: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
Days 1, 2, and 3 of Periods 1, 2, 3, and 4

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Participants With Death as Outcome, Serious Adverse Events, and Adverse Events (AEs) Leading to Discontinuation
Prazo: Continuously over Days 1 to 3 of treatment Periods 1, 2, 3, and 4
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Continuously over Days 1 to 3 of treatment Periods 1, 2, 3, and 4
Number of Participants With Clinically Significant Abnormalities in Hematology, Serum Chemistry, and Urinalysis Laboratory Test Results
Prazo: At screening visit, at Day -1 of Periods 1 through 4, and at discharge
Clinically significant was determined by the investigator. Hematology tests included hemoglobin, hematocrit, red blood cell count, total leukocyte count (including differential), and platelet count. Serum chemistry tests included aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, lactate dehydrogenase, creatinine, blood urea nitrogen, uric acid, fasting glucose, total protein, albumin, sodium, potassium, chloride, calcium, phosphorus, and creatine kinase. Urinalysis included protein, glucose, blood, leukocyte esterase, specific gravity, and pH.
At screening visit, at Day -1 of Periods 1 through 4, and at discharge
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Results
Prazo: At screening visit, Day -1 of Period 1, and at study discharge
Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.
At screening visit, Day -1 of Period 1, and at study discharge
Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate
Prazo: At screening visit, prior to dosing on Day 1 of Periods 1 through 4, and at study discharge.
Clinically significant was determined by the investigator. Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes.
At screening visit, prior to dosing on Day 1 of Periods 1 through 4, and at study discharge.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de março de 2010

Conclusão Primária (Real)

1 de março de 2010

Conclusão do estudo (Real)

1 de março de 2010

Datas de inscrição no estudo

Enviado pela primeira vez

12 de fevereiro de 2010

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de fevereiro de 2010

Primeira postagem (Estimativa)

15 de fevereiro de 2010

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

12 de maio de 2015

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de abril de 2015

Última verificação

1 de abril de 2015

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever